Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Biotin

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Biotin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia (phenotype)
  • Chronic kidney disease
  • Iron deficiency anemia
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Biotin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Biotin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.

    NCT04312152 · start 2019-03-09

    Registered record
    Registry ID
    NCT04312152
    Conditions
    Autism Spectrum Disorder; Phelan-McDermid Syndrome
    Interventions
    Q10 Ubiquinol; Vitamin E; Multi-Vitamin B complex
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-03-09
    Completion
    2023-08-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder; Phelan-McDermid Syndrome
    InterventionQ10 Ubiquinol; Vitamin E; Multi-Vitamin B complex
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Biotin on Routine Laboratory Values

    NCT03995277 · start 2019-01-11

    Registered record
    Registry ID
    NCT03995277
    Conditions
    Biotin Ingestion; Interference With Routine Analyical Tests
    Interventions
    Biotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-11
    Completion
    2019-08-01
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiotin Ingestion; Interference With Routine Analyical Tests
    InterventionBiotin
    PhasePhase 4
    Registry statusCompleted

  • The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters

    NCT03811756 · start 2018-10-15

    Registered record
    Registry ID
    NCT03811756
    Conditions
    Dermis Density; Trans Epidermal Water Loss (TEWL); Skin Hydration; Wrinkles; Dermis Thickness
    Interventions
    Test syrup containing CoQ10 and collagen; Placebo syrup
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-10-15
    Completion
    2019-07-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermis Density; Trans Epidermal Water Loss (TEWL); Skin Hydration; Wrinkles +1 more
    InterventionTest syrup containing CoQ10 and collagen; Placebo syrup
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis

    NCT03552211 · start 2018-05-30

    Registered record
    Registry ID
    NCT03552211
    Conditions
    Progressive Multiple Sclerosis
    Interventions
    biotin; propensity score
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-05-30
    Completion
    2019-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Multiple Sclerosis
    Interventionbiotin; propensity score
    PhaseNot recorded
    Registry statusUnknown

  • Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis

    NCT03427086 · start 2018-01-29

    Registered record
    Registry ID
    NCT03427086
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Biotin; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-29
    Completion
    2021-05-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionBiotin; Placebo Oral Tablet
    PhasePhase 2
    Registry statusCompleted

  • PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders

    NCT03300440 · start 2017-06-21

    Registered record
    Registry ID
    NCT03300440
    Conditions
    Mood Disorders; Depression
    Interventions
    Probiotics and vitamin B7; Placebo and vitamin B7
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-06-21
    Completion
    2019-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMood Disorders; Depression
    InterventionProbiotics and vitamin B7; Placebo and vitamin B7
    PhaseNot applicable
    Registry statusUnknown

  • Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

    NCT02483000 · start 2017-02-01

    Registered record
    Registry ID
    NCT02483000
    Conditions
    Burkitt Lymphoma; CD20-Positive Neoplastic Cells Present; Diffuse Large B-Cell Lymphoma; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory Mature B-Cell Non-Hodgkin Lymphoma
    Interventions
    Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein; Autologous Hematopoietic Stem Cell Transplantation; Carmustine; Clearing Agent; Cytarabine; Etoposide; Indium In 111-DOTA-Biotin; Laboratory Biomarker Analysis; Melphalan; Peripheral Blood Stem Cell Transplantation; Pharmacological Study; Yttrium Y 90-DOTA-Biotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-02-01
    Completion
    2020-09-02
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurkitt Lymphoma; CD20-Positive Neoplastic Cells Present; Diffuse Large B-Cell Lymphoma; Indolent Non-Hodgkin Lymphoma +3 more
    InterventionAnti-CD20 B9E9 scFv-Streptavidin Fusion Protein; Autologous Hematopoietic Stem Cell Transplantation; Carmustine; Clearing Agent +8 more
    PhasePhase 1
    Registry statusTerminated

  • Study of Biomarkers of the Response to Biotine

    NCT03215433 · start 2016-12-08

    Registered record
    Registry ID
    NCT03215433
    Conditions
    Multiple Sclerosis; Biotine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12-08
    Completion
    2019-01-23
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Biotine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

    NCT02967679 · start 2016-12-05

    Registered record
    Registry ID
    NCT02967679
    Conditions
    Chronic Inflammatory Demyelinating Polyneuropathy; Peripheral Neuropathy; Charcot-Marie-Tooth Disease; Charcot-Marie-Tooth Disease Type 1A; Charcot-Marie-Tooth Disease, Type 1B; Anti-MAG Neuropathy
    Interventions
    MD1003
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-05
    Completion
    2019-03-18
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Inflammatory Demyelinating Polyneuropathy; Peripheral Neuropathy; Charcot-Marie-Tooth Disease; Charcot-Marie-Tooth Disease Type 1A +2 more
    InterventionMD1003
    PhasePhase 2
    Registry statusCompleted

  • Effect of MD1003 in Amyotrophic Lateral Sclerosis

    NCT03114215 · start 2016-06-29

    Registered record
    Registry ID
    NCT03114215
    Conditions
    ALS; Amyotrophic Lateral Sclerosis; Motor Neuron Disease
    Interventions
    MD1003; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06-29
    Completion
    2017-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALS; Amyotrophic Lateral Sclerosis; Motor Neuron Disease
    InterventionMD1003; Placebo oral capsule
    PhasePhase 2
    Registry statusCompleted

  • TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA

    NCT02836340 · start 2016-05

    Registered record
    Registry ID
    NCT02836340
    Conditions
    Cardiac Arrest; Hypoxic Ischemic Brain Injury
    Interventions
    2-Iminobiotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-05
    Completion
    2020-04
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Arrest; Hypoxic Ischemic Brain Injury
    Intervention2-Iminobiotin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure

    NCT03563664 · start 2015-08-01

    Registered record
    Registry ID
    NCT03563664
    Conditions
    Unexplained Infertility
    Interventions
    Pre-treatment endometrial biopsy; Danazol; Post-treatment endometrial biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-01
    Completion
    2017-08-15
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnexplained Infertility
    InterventionPre-treatment endometrial biopsy; Danazol; Post-treatment endometrial biopsy
    PhasePhase 3
    Registry statusCompleted

  • Vitamin Gum Pharmacokinetics

    NCT03230396 · start 2014-10-13

    Registered record
    Registry ID
    NCT03230396
    Conditions
    Nutrient Pharmacokinetics
    Interventions
    Vitamingum Sport; Vitamingum Immunity; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-10-13
    Completion
    2015-07-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNutrient Pharmacokinetics
    InterventionVitamingum Sport; Vitamingum Immunity; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • MD1003-AMN MD1003 in Adrenomyeloneuropathy

    NCT02961803 · start 2014-10

    Registered record
    Registry ID
    NCT02961803
    Conditions
    Adrenomyeloneuropathy; Adrenoleukodystrophy; AMN
    Interventions
    MD1003 100 mg capsule; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2017-06
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenomyeloneuropathy; Adrenoleukodystrophy; AMN
    InterventionMD1003 100 mg capsule; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer

    NCT02053324 · start 2013-11-11

    Registered record
    Registry ID
    NCT02053324
    Conditions
    Liver Metastases
    Interventions
    AvidinOX/ST2210
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2013-11-11
    Completion
    2019-07-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Metastases
    InterventionAvidinOX/ST2210
    PhasePhase 1
    Registry statusTerminated